Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Director Janet Woodcock says user fee revenue will increase slowly, in part because some fees will not produce much revenue until the biosimilar industry expands.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
